This review looks at the mechanisms associated with resistance to Pseudomonas aeruginosa, as well as antibiotic combinations and limitations of current therapies, and the potential for alternative drugs and new therapeutic options are also discussed.
In this article the authors aim to harmonise the diagnosis of seasonal influenza and the approach of European general practitioners to vaccination in order to better identify influenza outbreaks and achieve a target vaccination rate of 75% throughout Europe.
In 2012, the Joint Committee on Vaccination and Immunisation recommended that the UK National Immunisation Programme for influenza be extended to include healthy children/adolescents aged 2–17 years. The extension of this new immunisation programme began in 2013–2014 and targeted children aged 2–3 years in primary care. This article describes the processes utilised in England and Scotland for programme setup, workforce management, identification and care of contraindicated patients, collection of data on vaccine uptake, communication strategies, and education of parents and children. In light of the lessons learnt from these pilot programmes, the authors make recommendations and offer practical advice to help ensure effective preparation and management of new childhood influenza vaccination programmes in other countries.
